Zymeworks Inc. Common Stock (ZYME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.41 Million) by net assets ($320.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ZYME equity financing ratio to measure how much of total assets are equity-financed.
Zymeworks Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ZYME cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Zymeworks Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pfeiffer Vacuum Technology AG
F:PFV
|
0.099x |
|
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
|
0.010x |
|
Grupo Televisa SAB ADR
NYSE:TV
|
0.029x |
|
Blackline Inc
NASDAQ:BL
|
0.137x |
|
Peugeot Invest SA
PA:PEUG
|
0.009x |
|
LuxNet
TWO:4979
|
0.097x |
|
Citic Offshore Helicopter Co Ltd
SHE:000099
|
0.009x |
|
Xinhuanet Co Ltd
SHG:603888
|
0.034x |
Annual Cash Flow Conversion Efficiency for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Zymeworks Inc. Common Stock from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Zymeworks Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $338.77 Million | $-110.04 Million | -0.325x | -27.63% |
| 2023-12-31 | $464.81 Million | $-118.30 Million | -0.255x | -187.06% |
| 2022-12-31 | $492.96 Million | $144.11 Million | 0.292x | +137.84% |
| 2021-12-31 | $249.09 Million | $-192.45 Million | -0.773x | -109.18% |
| 2020-12-31 | $409.92 Million | $-151.40 Million | -0.369x | -10.86% |
| 2019-12-31 | $245.68 Million | $-81.85 Million | -0.333x | -348.72% |
| 2018-12-31 | $180.49 Million | $24.18 Million | 0.134x | +7021.35% |
| 2017-12-31 | $116.43 Million | $219.00K | 0.002x | +100.05% |
| 2016-12-31 | $9.00 Million | $-35.25 Million | -3.915x | -222.11% |
| 2015-12-31 | $18.24 Million | $-22.17 Million | -1.216x | -589.12% |
| 2014-12-31 | $39.78 Million | $-7.02 Million | -0.176x | -- |
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more